Minimal Residual Disease Testing Market Size, Growth, Trends | Report 2022-2030
The global minimal residual disease testing market was valued at USD 1.09 billion in 2021 and it is predicted to surpass around USD 3.70 billion by 2030 with a CAGR of 14.53% from 2022 to 2030.
MRD testing is essentially used in clinical and research applications for the detection of a residual disease condition. These tests are used for the detection of either hematological malignancies or solid tumors. Continuous monitoring of residual cancer cells throughout the core treatment and during the remission stage fetches the oncologists with personalized insights on the efficacy of the used therapy. It also precisely predicts the risk of a possible relapse of the condition. MRD testing influences treatment choices to yield better therapeutic outcomes.
The use of MRD testing as a novel prognostic and diagnostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. It generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. For instance, in February 2022, the Foundation for National Institutes of Health’s Biomarkers Consortium launched a project for the validation of novel detection and quantification methods to effectively detect the trace amounts of carcinogenic cells left out in the body after a full-fledged anti-cancer therapy, and in cases of acute myeloid leukemia.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 1.09 billion |
| Revenue Forecast by 2030 | USD 3.70 billion |
| Growth rate from 2022 to 2030 | CAGR of 14.53% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Technology, Cancer Type, End use, Region |
| Companies Covered |
Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Arup Laboratories, F. Hoffmann- La Roche Ltd, Cergentis B.V., Guardant Health, ICON plc, Laboratory Corporation of America Holdings, Invivoscribe, Inc., Mission Bio, Inc., Opko Health, Natera, Inc., NeoGenomics Laboratories, Inc., Sysmex Corporation, Quest Diagnostics Incorporated |
Measurement of therapeutic outcomes are critical for the successful adoption of a given cancer therapeutic regime. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK’s hematology therapeutics.
Surgical removal of a tumor with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can still remain in the body parts and bloodstream. The diagnosis of such residual cells are crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a ‘software-as-a-medical-device’ MRD test in Europe.
Potential MRD diagnostics play a crucial role to make effective individual and long-term clinical decisions after the core cancer therapy. Moreover, MRD diagnostics efficiency is also important for healthcare insurance companies to effectively offer financial assistance to cancer survivors across the globe. For instance, in November 2021, Palmetto GBA's Molecular Diagnostics Program (MolDX) determined a medical expense cover that supported patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and B-cell acute lymphoblastic leukemia (ALL) for effectively monitoring the presence of residual cancer cells using the clonoSEQ platform.
Numerous MRD tests for the detection of residual solid tumors require tissue biopsy samples and deployment of patient-specific assays, which consumes longer turn-around time. Therefore, blood sample-based MRD detection assays are preferred. For instance, in January 2021 GRAIL, Inc., signed into a collaboration with Amgen, AstraZeneca, and Bristol Myers Squibb for evaluation of its MRD detection technology that is based on methylation.
Cancer therapeutics are effectively moderated to avoid leaving a residue of tumorous cells using the most relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are rising the need for consideration of individual genetic characteristics for effective treatment. For instance, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera’s diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.
Key Players
Market Segmentation
By Technology
By Cancer Type
By End use
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Minimal Residual Disease Testing Market
5.1. COVID-19 Landscape: Minimal Residual Disease Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Minimal Residual Disease Testing Market, By Technology
8.1. Minimal Residual Disease Testing Market, by Technology, 2022-2030
8.1.1 Next Generation Sequencing (NGS)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Polymerase Chain Reaction (PCR)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Flow Cytometry
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Minimal Residual Disease Testing Market, By Cancer Type
9.1. Minimal Residual Disease Testing Market, by Cancer Type, 2022-2030
9.1.1. Haematological Malignancy
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Haematological Malignancy
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Minimal Residual Disease Testing Market, By End use
10.1. Minimal Residual Disease Testing Market, by End use, 2022-2030
10.1.1. Hospitals & Diagnostic Laboratories
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Academic & Research Institutes
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Minimal Residual Disease Testing Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.1.3. Market Revenue and Forecast, by End use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.3. Market Revenue and Forecast, by End use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.3. Market Revenue and Forecast, by End use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.3. Market Revenue and Forecast, by End use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.5.3. Market Revenue and Forecast, by End use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End use (2017-2030)
Chapter 12. Company Profiles
12.1. Adaptive Biotechnologies Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bio-Rad Laboratories, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Arup Laboratories
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann- La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Cergentis B.V.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Guardant Health
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. ICON plc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Laboratory Corporation of America Holdings
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Invivoscribe, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Mission Bio, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers